Kurzfassung

A phase 3, randomized, double-blind, placebo-controlled study
evaluating the efficacy and safety of Idelalisib (GS-1101) in
combination with Bendamustine and Rituximab for previously
treated indolent Non-Hodgkin Lymphomas